Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31619417 | 0.87 | ALDH1A1 (0.35) | ALDH1A1EGLN1 | |
| SCHEMBL3536872 | 0.87 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL21594961 | 0.83 | ALDH1A1 (0.32) | ALDH1A1TET2EGLN1 | |
| SCHEMBL28746307 | 0.81 | ALDH1A1 (0.31) | ALDH1A1TET2EGLN1 | |
| SCHEMBL884967 | 0.81 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL23391871 | 0.79 | MGAM (0.39) | ALDH1A1 | |
| SCHEMBL4976326 | 0.79 | MGAM (0.39) | ALDH1A1TET2TSHR | |
| SCHEMBL19677667 | 0.79 | EGLN1 (0.38) | ALDH1A1EGLN1TSHR | |
| SCHEMBL14337086 | 0.76 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL29127995 | 0.75 | CES1 (0.46) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118420456-A | Method for preparing 2, 2-dimethyl difluoromalonate by flow chemistry | 上海友直医药科技有限公司 | 2024-08-02 | — | — | CN | claimed |
| EP-4720067-A1 | BICYCLIC HETEROARYLAMIDES HAVING GPR68 MODULATING ACTIVITY | Recursion Pharmaceuticals, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| US-12503438-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250221966-A1 | RXFP1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-07-10 | — | — | US | disclosed |
| WO-2025073822-A1 | STRAINED MULTI-FUNCTIONALIZED TRANS-CYCLOOCTENES | STICHTING RADBOUD UNIVERSITEIT (NL) | 2025-04-10 | — | — | WO | disclosed |
| WO-2024246559-A1 | BICYCLIC HETEROARYLAMIDES HAVING GPR68 MODULATING ACTIVITY | EXSCIENTIA AI LIMITED (GB) | 2024-12-05 | — | — | WO | disclosed |
| EP-4422746-A1 | RXFP1 AGONISTS | Bristol-Myers Squibb Company (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118420456-A | Method for preparing 2, 2-dimethyl difluoromalonate by flow chemistry | 上海友直医药科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20240254146-A1 | FLUORINATED POLY(PYRIDYL)-BORATE LIGANDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-08-01 | — | — | US | disclosed |
| EP-1992628-A1 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2008-11-19 | — | — | EP | disclosed |
| US-20080114049-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| WO-2008031772-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | GLAXO GROUP LIMITED (GB) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008009700-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
| US-20050010059-A1 | Chemical reagents capable of selective attachment to and reaction with peptides and proteins | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2005-01-13 | — | — | US | disclosed |
| EP-1178968-A4 | A PROCESS FOR THE REDUCTION OF OXIRANYL EPOTHILONES TO OLEFINIC EPOTHILONES | BRISTOL MYERS SQUIBB CO (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-1178968-A1 | A PROCESS FOR THE REDUCTION OF OXIRANYL EPOTHILONES TO OLEFINIC EPOTHILONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-02-13 | — | — | EP | disclosed |
| US-6320045-B1 | REDUCTION WITH A METAL, METALLOCENE OR METAL-ASSISTED REAGENT, E.G., DIMETHYL DIAZOMALONATE ACTIVATED BY A RHODIUM CATALYST | BRISTOL-MYERS SQUIBB COMPANY | 2001-11-20 | — | — | US | disclosed |
| WO-2000071521-A1 | A PROCESS FOR THE REDUCTION OF OXIRANYL EPOTHILONES TO OLEFINIC EPOTHILONES | BRISTOL-MYERS SQUIBB CO. (US) | 2000-11-30 | — | — | WO | disclosed |
| EP-0222703-A1 | Hexahydro-[1]-benzo-(pyrano and thiopyrano)-[4,3-c] pyridines | CIBA-GEIGY AG (CH) | 1987-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050010059-A1 | Chemical reagents capable of selective attachment to and reaction with peptides and proteins | PTMS, FGB, DNPEP | ALDH1A1 4309/4885TET2 4620/4885EGLN1 3959/4885 |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | IKZF1, IKZF2, BCL6 | ALDH1A1 2574/4885TET2 3651/4885EGLN1 1186/4885 |
| US-20250221966-A1 | RXFP1 AGONISTS | RXFP1, RXFP2, RXFP3 | ALDH1A1 1820/4885TET2 4574/4885EGLN1 1868/4885 |
| US-12503438-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, ERBB3, PTK2B | ALDH1A1 3579/4885TET2 4113/4885EGLN1 1771/4885 |
| US-20240254146-A1 | FLUORINATED POLY(PYRIDYL)-BORATE LIGANDS | PARG, PARN, PCBP1 | ALDH1A1 4502/4885TET2 3190/4885EGLN1 4716/4885 |
| US-20080114049-A1 | CHEMICAL COMPOUNDS | SLC6A2, HTR3C, SLC6A3 | ALDH1A1 219/4885TET2 796/4885EGLN1 3118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.